D L Watson1, M L McColl, H I Davies. 1. CSIRO Division of Animal Production, Pastoral Research Laboratory, Armidale, New South Wales.
Abstract
OBJECTIVE: To assess the efficacy of a new staphylococcal mastitis vaccine under commercial dairying conditions. DESIGN: A field trial involving 1819 cows and heifers conducted on seven dairy herds in Victoria. The trial was done 'blind'; approximately half the animals were vaccinated and the remainder were untreated controls. PROCEDURE: The vaccine was given twice during the last 10 weeks of pregnancy. Effects of vaccination were assessed, during the ensuing lactation, on the basis of clinical and sub-clinical mastitis and microbiological investigations of the milk. RESULTS: A total of 273 cases of clinical mastitis were recorded. Staphylococcus aureus was isolated from 112 of these, 45 cases in vaccinates and 67 cases in controls; the difference was not statistically significant. One herd was notable in having a high incidence of clinical staphylococcal mastitis. This herd accounted for 15.8% of the animals in the field trial but 54.5% of cases of clinical staphylococcal mastitis. For this herd, vaccinated animals had significantly lower incidence of clinical staphylococcal mastitis and prevalence of subclinical mastitis, relative to controls. An unexpected feature of the trial as a whole was the low incidence of clinical mastitis from which S aureus was isolated in pure culture (26.3% of cases) and the high incidence of clinical Streptococcus uberis mastitis (22.7% of cases). CONCLUSIONS: The trial showed that the vaccine was efficacious in reducing the incidence of clinical mastitis and prevalence of subclinical mastitis in a herd that had a serious staphylococcal mastitis problem.
OBJECTIVE: To assess the efficacy of a new staphylococcal mastitis vaccine under commercial dairying conditions. DESIGN: A field trial involving 1819 cows and heifers conducted on seven dairy herds in Victoria. The trial was done 'blind'; approximately half the animals were vaccinated and the remainder were untreated controls. PROCEDURE: The vaccine was given twice during the last 10 weeks of pregnancy. Effects of vaccination were assessed, during the ensuing lactation, on the basis of clinical and sub-clinical mastitis and microbiological investigations of the milk. RESULTS: A total of 273 cases of clinical mastitis were recorded. Staphylococcus aureus was isolated from 112 of these, 45 cases in vaccinates and 67 cases in controls; the difference was not statistically significant. One herd was notable in having a high incidence of clinical staphylococcal mastitis. This herd accounted for 15.8% of the animals in the field trial but 54.5% of cases of clinical staphylococcal mastitis. For this herd, vaccinated animals had significantly lower incidence of clinical staphylococcal mastitis and prevalence of subclinical mastitis, relative to controls. An unexpected feature of the trial as a whole was the low incidence of clinical mastitis from which S aureus was isolated in pure culture (26.3% of cases) and the high incidence of clinical Streptococcus uberis mastitis (22.7% of cases). CONCLUSIONS: The trial showed that the vaccine was efficacious in reducing the incidence of clinical mastitis and prevalence of subclinical mastitis in a herd that had a serious staphylococcal mastitis problem.
Authors: Jai-Wei Lee; Celia N O'Brien; Albert J Guidry; Max J Paape; Kimberley A Shafer-Weaver; X Zhao Journal: Can J Vet Res Date: 2005-01 Impact factor: 1.310
Authors: Takehiro Tomita; Brian Meehan; Nalin Wongkattiya; Jakob Malmo; Gillian Pullinger; James Leigh; Margaret Deighton Journal: Appl Environ Microbiol Date: 2007-11-16 Impact factor: 4.792
Authors: M M Pérez; A Prenafeta; J Valle; J Penadés; C Rota; C Solano; J Marco; M J Grilló; I Lasa; J M Irache; T Maira-Litran; J Jiménez-Barbero; L Costa; G B Pier; D de Andrés; B Amorena Journal: Vaccine Date: 2009-02-12 Impact factor: 3.641